From owner-repertoires@net.bio.net Sun Jan 04 22:00:00 1998 Path: biosci!biosci!not-for-mail From: palella@palella.com (David A. Palella) Newsgroups: bionet.molecules.repertoires Subject: GENOMICS CONFERENCES & UPDATE RE CYBERCHEMICS, INC. (CCI) Date: 5 Jan 1998 01:49:11 -0800 Organization: BIOSCI International Newsgroups for Molecular Biology Lines: 463 Sender: daemon@net.bio.net Approved: A.Wallace@Queens-Belfast.AC.UK Distribution: world Message-ID: <68q89a$9tb@mserv1.dl.ac.uk> NNTP-Posting-Host: net.bio.net Dear Madame or Sir, 30 December 97 We invite you to meet with our client, CyberChemics, Inc. (CCI), the premier company worldwide applying leading-edge artificial intelligence technologies to lead discovery & optimization in both biopharmaceuticals and bioagriculture, at the two conferences listed below. Representatives of CyberChemics will either attend or present a paper at these events. Please note that we have absolutely NO financial relationship with any of the conferences mentioned herein, so please contact the conference organizers directly with any questions regarding these events: (1) FUNCTIONAL GENOMICS: FROM IDENTIFYING PROTEINS to FASTER DRUG DISCOVERY (March 10 - 11, 1998) Location: Washington, DC, The Westin City Center. Conference Organizer: NMHCC, INC. 71 Second Avenue, 3rd Floor Waltham, MA 02154 USA Main tel: 781-663-6000/888-882-2500 Contact Person: Mr. Ed HOLLAND Director of Special Programs Direct tel: 781-663-6552 Fax: 617-663-6429 Email: edh@nmhcc.com ..................................................................... (2) PLANT & ANIMAL GENOME CONFERENCE VI (January 18-22, 1998) Location: San Diego, California, Town & Country Hotel Conference Organizer: Scherago International 11 Penn Plaza NYC, NY 10001 USA Tel: 212-643-1750 Fax: 212-643-1758 Web site: http://www.scherago.com Contact Person: Mr. Darrin SCHERAGO Tel: 212-643-1750, ext. 20 Email: darrins@scherago.com Description: In its sixth year, the Plant & Animal Genome Conference is the largest meeting that focuses specifically on transgenic agricultural plants and animals. Since the first conference, attendance has more that doubled to 850 delegates from agricultural research facilities throughou= t the world. Sponsors and supporters include the USDA/ARS, USDA/NAL, USDA/NRI, John Innes Center, The Rockefeller Foundation, and the International Society for Plant Molecular Biology and USDA/CSREES. ..................................................................... If you have interest to arrange a meeting with a representative of CybeChemics, please contact myself or: David NOEVER, Ph.D. Chairman & Founder CYBERCHEMICS, INC. 500 Blvd. South, Suite 101 Huntsville, AL 35802 USA tel: 205-881-8805 fax: 205-881-3372 Email: cybchemx@ro.com (D. Noever) Web site: http://ro.com/~cybchemx/index.html =46inally, recent developments at CyberChemics are described in the newsreleases appended below. We look forward to seeing you at these excellent conferences in the near future. With season's greetings & best wishes for a healthy, happy & prosperous 1998= ! David Palella, President BIOSCIENCE VENTURES, INC. attachments ------------------------------------------------------------------------- CCI SOURCE: CyberChemics, Inc. DATE: December 1, 1997 SUBJECT: News -- For Immediate Release CYBERCHEMICS, INC. TO PRESENT PAPER ON "E. COLI AND CANDIDA GENOME SEQUENCING: FROM DNA TO DRUGS" AT FUNCTIONAL GENOMICS CONFERENCE IN WASHINGTON DC Huntsville, AL-December 1, 1997--CyberChemics, Inc. (CCI) announced today that Dr. David A. Noever, CCI's chairman will present a paper entitled, "E coli and Candida Genome Sequencing: from DNA to Drugs" to attendees of the international Functional Genomics Conference in Washington, DC, March 10-11, 1998 at the Westin City Center. The March conference, sponsored by NMHCC, is focusing on themes "From Identifying Proteins to Faster Drug Discovery". Dr. Noever will explain how CCI's evolutionary computational applications of drug screening (In Virtuo=81 screening) are being used to increase the Company's extensive library of linear antifungal peptides and specific lead peptides active against antibiotic-resistant Candida and E. coli pathogens. In vitro, these peptides manifest an unprecedented and rapid six log-orders reduction in fungal population counts, in effect, acting almost as "bio-sterilants." According to Dr. Noever, "all peptide defensins currently on the market or in development, such as protegrins, tachyplesins, and insect-derived cecropins, cannot function as effective transgenic antifungals or anti-bacterials because of their dependence on secondary structures, mainly disulfide bonds which may or may not be genetically expressible in all physiological systems. The best solution to this problem is to computationally identify and isolate naturally occurring linear peptides from the genomes of multiple organisms with predicted antifungal and/or antibacterial mechanisms." The greater benefit of transplanting pieces of DNA into a target genome (transgenics), e.g., into corn or soybeans, aside from the initial control of fungus and bacterium, is that the planned effect will be permanent and recurring in successive cell generations. A relatively new field, transgenics is earning the respect of both government and commercial crop protection experts. Peptide antifungal derivatives are especially useful in agricultural and agronomic settings in which the peptides could be used on the plants, e.g., as a spray, or incorporated into a plant genome -- genetically engineering a plant cell so that the plant cell itself produces the peptide. On October 27, 1997, President Clinton signed into law the VA-HUD bill (P.L. 105-65) which approves $40 million to be spent by the National Science Foundation on a Plant Genome Initiative. In conjunction with this initiative, the National Corn Genome Initiative Report, stated, "The future demand (quantity and quality) cannot be met using the technology which has been so successful in the past. It is critical that a breakthrough be created to meet the food supply needs, the level of quality desired, and the development of more sustainable production methods. New development in precision agriculture, and in information technology, will contribute to improved efficiency -- but it is the genetic code which carries the solution to breakthrough technology, and creating a new foundation which the other approaches can build from." Prior to the proprietary computational efforts of CCI to classify and design peptide antifungals de novo, a facile method of identification of new or improved compounds was not available. CCI's world-class core technology figures prominently among those rapidly expanding techniques sometimes called, "Evolutionary Computation". Many of these methods derive from decades of research focused on developing practical and functional machine intelligence, such as genetic algorithms, which simulate breeding strategies, and neural networks, which implement high-level pattern recognition. =46OR ADDITIONAL INFORMATION: Ms. Alana Proctor/Dr. David Noever Corporate Communications CyberChemics, Inc. 500 Boulevard South, Suite 101 Huntsville, AL 35802 USA 205-881-8805/205-881-3372 (F) E-mail: cybchemx@ro.com Web site: http://ro.com/~cybchemx/ ------------------------------------------------------------------------- Non-confidential Technology Backgrounder ---------------------------------------- CyberChemics, Inc.'s In-house Supercomputer Capability: Proprietary Know-how at a Fraction of Supercomputer Cost Massively-parallel computers, such as CyberChemics' (CCI's) proprietary, in-house supercomputer, operate on an entirely different set of functional assumptions versus a traditional serial computer. As its name partially implies, a massively-parallel computer is one that contains multiple processors that operate harmoniously. Traditional computers center their computations on a single processor, in the same manner as the human mind works with only one central processor. The complication behind massively-parallel computers lie in their design relationship to the task at hand. Unlike serial computers, a massively-parallel computer must be custom built to the specifications of the formula, or scope of formulas, it will be processing. As developed in-house in a proprietary chip for drug discovery, CCI can typically scan a search space of as many as a billion billion (10 raised to the power 18) potential small-molecule building blocks or amino acid sequences before arriving at a directed library of the 100 most-probable candidates for subsequent synthesis and testing. The system currently accommodates heterocyclics, bicyclics, fused rings, aromatic rings, D/L amino acids, Beta/Alpha-D sugars, nucleotides/bases and carbonyls. This scanning capability takes advantage of proprietary CCI software that is implemented seamlessly onto 64 parallel processors (e.g. directly in hardware or evolvable 'firmware'), thus delivering what represents an industry-standard for large- scale proprietary computational discovery programs. The design of new compounds or their subsequent optimization is thereby done directly in hardware and on a proprietary customized chip -- a unique feature called the CyberChemics Rosetta(TM) system that can compete effectively with a supercomputer (>3 billion connections/ second, or equivalently < one nanosecond calculation times or 3 GigaFLOPs). Thus, what may have previously taken a dedicated computer approximately 3-5 years to accomplish is at least shortened by a factor of 1000 -- or accomplished= in a single day's work. Even if current workstations double their calculation speed every 18 months, as they traditionally have, such a computational capability as that already operational at CyberChemics will not be matched in a similar desktop environment in the next two decades, i.e., until the year 2017. CCI's chemical and biological testing experience to date would indicate that= in the case of discovery libraries, among the 100 rank-ordered compounds finall= y selected, active leads can be identified in greater than 70 (seventy) % of those in which synthesis is undertaken. This CCI method is novel among the growing efforts in combinatorial chemistry, particularly in its ability to both diversify and select most-active probable sequences or structures using computer algorithms developed in-house specifically for this use. The CyberChemics' Rosetta(TM) system is a full development system based on a proprietary Digital Parallel Processor chip that has 64 sub-processors operating in a single-instruction, multiple-data (SIMD) architecture. Each sub-processor has its own 4k bytes of local memory and a fixed point arithmetic unit to perform 1-bit, 8-bit, or 16-bit integer arithmetic. Each sub-processor can emulate one or more learning techniques and multiple chips can be ganged together. When implemented in hardware, all simulations can take advantage of their inherent parallelism and run orders of magnitude faster than software simulations. This execution speed is three times that of the 1988 Gordon Bell Prize-winning entry for the world's premier supercomputer, twenty-four times that of the 1987 winning entry, and even exceeds the theoretical peak calculation speed of many, much more expensive conventional supercomputers in use today. The National Science Foundation designated such simulation capacity as one of the twenty national Grand Challenges in science and engineering with broad economic and scientific impact. These Grand Challenges are generally considered intractable without the use of state-of-the-art, massively-parallel computers. For comparison as an industry standard, the University of Mannheim in Germany maintains a Top- 500 list of the world's fastest supercomputers. In relation to supercomputer vendors, for example, Digital's supercomputer capacity performs 6.7 GigaFLOPs, the Caltech Center for Advanced Computing Resources' 12-node IBM SP-2 runs at 4.4 GigaFLOPs, and 4-16 processors in the Cray J90 and Cray C94/264 supercomputers run from 0.8-3.2 GigaFLOPs. While in classified work, the current gold standard for such supercomputer calculation speeds is approaching a 1,000-times higher rate (i.e., TeraFLOPs= ), multiple users and limited access times restrict the application of these ne= xt- generation machines in real-world drug discovery. Thus, CyberChemics' capability would rank it in the Top-500 of all computers ever assembled as late as November 1995 (benchmark, 2.5 GigaFLOPs). And because this list includes classified, government and vendor-owned supercomputers with multiple users, the proprietary know-how associated with CyberChemics' in-house, desktop implementation in a dedicated workstation environment provides unprecedented opportunities for delivering state-of-the-art discovery tools to CCI's corporate partners, and for answering lead discovery and optimization questions previously thought to be computationally intractable. (end of Technology Backgrounder) ------------------------------------------------------------------------- CCI SOURCE: CyberChemics, Inc. DATE: August 18, 1997 SUBJECT: News--For Immediate Release CYBERCHEMICS, INC. PRESENTS PAPER ON "IN VIRTUO=81 SCREENING OF HIV PROTEASE INHIBITORS IDENTIFIED FROM SOYBEANS" AT CONFERENCE ON PROTEASE INHIBITORS IN INFECTIOUS DISEASE, PHILADELPHIA, PA Huntsville, AL -- August 18, 1997 -- CyberChemics, Inc. (CCI) announced the participation of scientists from the company, including one of its founders, Dr. David Noever, at the International Conference on Protease Inhibitors in Infectious Diseases, 17-18 August, in Philadelphia, PA. Dr. Noever is presenting the paper, "In Virtuo=81 Screening of HIV Protease Inhibitors Identified from Soybean Proteins," and will discuss features of natural product screening for antivirals using combined computational and high-throughput methods. The presentation was highlighted in the National Managed Health Care Congress (NMHCC) advance program, and the conference includes global participants from research universities, along with pharmaceutical and biotechnology companies involved in antiviral and protease inhibitor (PI) development. "The reported results will describe the power and efficiency of natural product screening using non-traditional methods of high-throughput computational assays and evolutionary computation", said Andrew Brittain, Ph.D., President of CCI. "New drug leads developed by otherwise trial-and-error discovery methods are capital- and labor-intensive and often yield an unacceptably high rate of duplication of known structures. An oft-cited example of this traditional approach is the high-cost, but frequently encountered, rediscovery of known antibiotic and antiviral compounds. Streptomycin, an historically important antibiotic found in natural soil samples, is probably rediscovered by traditional natural product screening as many as 100 times a year in dozens of labs around the world. CCI is developing powerful artificial intelligence-based computational methods to ensure increased chemical diversity in drug discovery, and also to avoid late-stage abandonment of lead compounds. Because CCI's proprietary selection methods for chemical synthesis -- so called In Virtuo=81 or computational selection -- can simultaneously optimiz= e the following list of lead properties, the probability of eventual clinical success is dramatically increased: activity (potency); low toxicity (LD50); bioavailability (log P, in vivo half-life); solubility; yield (ease of synthesis or favored transgenic protein expression); purity; pH stability; oxidative stability; molecular weight; high or low ionic (salt) stability; selectivity toward a target (organisms such as gram negative vs. gram positive bacteria, fungi, broad vs. narrow spectrum potency); protease susceptibility; cyclizability; conformational or chiral aspects (e.g. alpha-helical character); adhesion or anti-adhesion as secondary properties (wound healing, coatings); and cryogenic and/or thermal stability." Because amino acid sequences exhibiting protease inhibitory activity comprise as much as 5% of the total protein weight of soybeans, this traditional food crop is considered a promising natural source for novel, low cost protease inhibitors. Forming an essential part of the plant's natural insect resistance, peptidyl protease inhibitors in nature are found most frequently in soybeans -- a cultivated source second only to a relatively rare wild tomato seed for its total PI content. CCI's world-class core technology figures prominently among those rapidly expanding techniques sometimes called, "Evolutionary Computation". Many of these methods derive from decades of research focused on developing practical and functional machine intelligence, such as genetic algorithms, which simulate breeding strategies, and neural networks, which implement high-level pattern recognition. ------------------------------------------------------------------------- CCI SOURCE: CyberChemics, Inc. DATE: April 1, 1997 SUBJECT: News--For Immediate Release CYBERCHEMICS, INC. ANNOUNCES PROPRIETARY ALGORITHMS FOR COMPUTATIONAL OPTIMIZATION AND PREDICTION OF TRANSGENIC PROTEIN YIELD IN MAMMARY GLAND AND OTHER ANIMAL & PLANT SYSTEMS Huntsville, AL -- April 1, 1997 -- CyberChemics, Inc. (CCI) announced the development of the world's first computational algorithm using protein sequence data only, to give better than 80 - 90% predictability for transgenic yield of a protein in mammary gland. Once costly and time-consuming trial-and-error expression experiments can now be predicted computationally prior to undertaking a development and production program. CyberChemics' proprietary neural network algorithm combines data from more than 100,000 gene constructs, proteins and fragments extracted from the Sinai Mammary Transgene Database. This proprietary software can: (1) identify and classify difficult-to-express segments (<20 aa or less) of a larger protein, thus allowing a highly-focused program for site-directed mutagenesis and higher yields in the target protein (2) suggest "point and click" modifications on a site-by-site basis to identify single residues which may hinder expression; and (3) suggest new expression systems or mammalian species for higher yield. Moreover, by using a windowing step, proteins of any size can be accommodated for data entry. Hence, the production of such important proteins as human growth hormone, lysozyme or beta-casein can now be optimized for yield and ease of transgenic synthesis by a priori manipulation of coding and regulatory sequence, host species selection, RNA, protein and/or activity levels. Future efforts will extend the same powerful methodology to plant- and seed-based production of transgenic proteins of biotechnological importance. One of the most frequently-cited examples of successful expression in the field of transgenic protein production centers on a $17 million collaboration for transgenic production of human serum albumin. However, it took four years to achieve a 50% yield in a transgenic mouse model, whereas the same results can now be obtained in minutes using the neural net technology developed by CCI. In sum, collaborative implementation of CCI's proprietary neural net-based algorithms for specific target proteins can result in highly significant competitive advantages for corporate partners in terms of dramatically reduced time-to-market, greatly decreased product development costs and much higher transgenic yields. CCI's world-class core technology figures prominently among those rapidly expanding techniques sometimes called, "Evolutionary Computation". Many of these methods derive from decades of research focused on developing practical and functional machine intelligence, such as genetic algorithms, which simulate breeding strategies, and neural networks, which implement high-level pattern recognition. (End of Newsreleases) ************************************************************************** Welcome to the BioScience Ventures, Inc. email distribution list composed of our friends and colleagues in several professional societies and business groups. The purpose of this list is: (1) to advise you of SIGNIFICANT news regarding our North American and Japanese pharma & diagnostic clients; and (2) to highlight WORLD-CLASS biopharma and biotech conferences taking place on the U.S. West Coast. Please note that we have NO financial connection with any of the conferences mentioned herein, so please contact the conference organizers directly with any questions regarding such events. This list will be used no more than twice/MONTH and will NOT be made available to third parties. Beware! If you do not find one or more of these infrequent emails of great interest, then you may have no interests. To be deleted from this list, simply reply to this message. With best wishes, David A. Palella, President BIOSCIENCE VENTURES, INC. ------------------------------------------------------- ** International Strategic Alliances for the Life Sciences ** 2658 Del Mar Heights Road Suite 267 Del Mar, California 92014 USA Tel: 619-793-0741 Fax: 619-793-0742 Main email: palella@palella.com Alternate email: palella@aol.com Web sites: http://www.palella.com/palella/ OR: http://www.biospace.com/exhib_script/exhibitors/BioScienceVenturesInc.cfm From owner-repertoires@net.bio.net Sun Jan 04 22:00:00 1998 Path: biosci!biosci!not-for-mail From: ic@clara.net (AT) Newsgroups: bionet.molecules.repertoires Subject: Amino Acid Transportation in bacteria Date: 5 Jan 1998 06:17:12 -0800 Organization: BIOSCI International Newsgroups for Molecular Biology Lines: 19 Sender: daemon@net.bio.net Approved: A.Wallace@Queens-Belfast.AC.UK Distribution: world Message-ID: <68qq18$hlh@net.bio.net> NNTP-Posting-Host: net.bio.net Hi, Does anyone have any idea about what (and which) web sites would be the best to look for different properties of chemicals listed, and how they effect the Amino Acid Transportation in bacteria:- carbonylcyanide m-chlorophenyl hydrazone (CCCP) Valinomycin Nigericin Thank you. John K. King Please reply to ic@clara.net From owner-repertoires@net.bio.net Wed Jan 07 22:00:00 1998 Path: biosci!biosci!not-for-mail From: Wendy Warr Newsgroups: bionet.molecules.repertoires Subject: Meetings lists Date: 8 Jan 1998 03:21:36 -0800 Organization: BIOSCI International Newsgroups for Molecular Biology Lines: 50 Sender: daemon@net.bio.net Approved: A.Wallace@Queens-Belfast.AC.UK Distribution: world Message-ID: <692bq1$dfq@mserv1.dl.ac.uk> NNTP-Posting-Host: net.bio.net We have just done a major meetings update to http://www.warr.com. We list meetings in the following fields: drug discovery (but not meetings that are essentially for biologists or biotechnologists) combinatorial chemistry computational chemistry scientific, technical, and (some) medical information knowledge management electronic publishing competitive intelligence and strategic information IT (if particularly relevant to the pharmaceutical industry) We have some meetings but do not aim to be comprehensive in: organic chemistry analytical chemistry chemometrics pharmaceutical ingredients, custom chemicals, chiral drugs laboratory instrumentation librarianship pesticides Please check and see that we have listed your meeting(s) OK. Also, please do keep sending us meeting details at regular intervals (especially in electronic form). If your meeting is chemical but it does not fit into a category we handle, we will send it to ChemWeb.com. You can input meetings yourself to the ChemWeb events list - visit http://ChemWeb.com. (Please excuse duplicate postings. At least I've spared you the enormous circulation list by using blind copy.) Wendy Warr Dr Wendy A Warr Wendy Warr & Associates, 6 Berwick Court Holmes Chapel, Cheshire CW4 7HZ, England Tel/fax +44 (0)1477 533837 wendy@warr.com http://www.warr.com From owner-repertoires@net.bio.net Thu Jan 08 22:00:00 1998 Path: biosci!biosci!not-for-mail From: Willi Glettig Newsgroups: bionet.molecules.repertoires Subject: Reproducible methods for quantifying hydroxyl, carboxyl and carbonyl Date: 9 Jan 1998 04:43:11 -0800 Organization: BIOSCI International Newsgroups for Molecular Biology Lines: 27 Sender: daemon@net.bio.net Approved: A.Wallace@Queens-Belfast.AC.UK Distribution: world Message-ID: <69556h$3q5@mserv1.dl.ac.uk> NNTP-Posting-Host: net.bio.net Dear Solid Phase Chemist / Combinatorial Chemist How do you quantify OH, Carboxyl and Carbonyl functional groups in low level crosslinked Polystyrene beads? As we all know, there are a number of methods to quantify functional e.g. amino groups in Polystyrene beads, - each method producing different results. As manufacturers of the most precise solid phase materials we are interested to learn how you assess quantity of above functional groups? We are interested to find and apply the most reproducible methods. We are interested not only in assessing mmol/g but also in kinetic data . Please send you comment to Willi Glettig LCC Engineering & Trading GmbH CH - 4622 Egerkingen Switzerland Tel: + 41 (0)62 398 52 71 Fax.: + 41 (0)62 398 52 74 E-Mail: wglettig@mail.tic.ch From owner-repertoires@net.bio.net Sun Jan 11 22:00:00 1998 Path: biosci!biosci!not-for-mail From: Bill Town Newsgroups: bionet.molecules.repertoires Subject: ChemDex Plus is now available on ChemWeb Date: 12 Jan 1998 09:28:29 -0800 Organization: BIOSCI International Newsgroups for Molecular Biology Lines: 24 Sender: daemon@net.bio.net Approved: A.Wallace@Queens-Belfast.AC.UK Distribution: world Message-ID: <69dfrv$prr@mserv1.dl.ac.uk> NNTP-Posting-Host: net.bio.net ChemWeb is pleased to announce that ChemDex Plus is now available on ChemWeb: http://chemweb.com/databases/chemdex/chemdex.exe ChemDex Plus is a fully searchable version of the ChemDex Directory developed by Mark Winter of the University of Sheffield containing of thousands of chemistry resources on the world wide web. Later this year an extended second version of ChemDex Plus will be released. This will have enhanced searching and browsing features and linked sites will be reviewed and evaluated. Bill Town Director of Operations, ChemWeb, Inc. e-mail: billt@cursci.co.uk URL: http://chemweb.com From owner-repertoires@net.bio.net Sun Jan 11 22:00:00 1998 Path: biosci!biosci!not-for-mail From: sara ingrassia Newsgroups: bionet.molecules.repertoires Subject: anti-pVIII Date: 12 Jan 1998 04:44:49 -0800 Organization: BIOSCI International Newsgroups for Molecular Biology Lines: 12 Sender: daemon@net.bio.net Approved: A.Wallace@Queens-Belfast.AC.UK Distribution: world Message-ID: <69d2r3$d2n@mserv1.dl.ac.uk> NNTP-Posting-Host: net.bio.net Dear Phage Displayers, Is anyone aware of an anti pVIII( better if HRP conjugate)? Thank you very much for the advise. Sincerely, Sara From owner-repertoires@net.bio.net Wed Jan 21 22:00:00 1998 Path: biosci!biosci!not-for-mail From: Wendy Warr Newsgroups: bionet.molecules.repertoires Subject: Award for BS/MS Chemists Date: 22 Jan 1998 01:55:51 -0800 Organization: BIOSCI International Newsgroups for Molecular Biology Lines: 37 Sender: daemon@net.bio.net Approved: A.Wallace@Queens-Belfast.AC.UK Distribution: world Message-ID: <6a74dc$o4o@mserv1.dl.ac.uk> NNTP-Posting-Host: net.bio.net (With apologies for duplicate postings) BS/MS Chemists Sought for Technical Achievement Awards The Organic Division of the ACS is seeking to increase the involvement of Bachelor's- and Master's-level chemists in Divisional activities. Although these individuals regularly make important contributions in the workplace, all too often they receive little or no recognition for their efforts from the scientific community. As one of the means to address this situation, the Organic Division has instituted an annual symposium at the Fall ACS meeting to recognise the achievements of non-Ph.D. chemists. They are now seeking nominations for the coming year's programme. The seventh annual Symposium on Technical Achievements in Organic Chemistry will be held at the 216th National Meeting of the ACS in Boston, Massachusetts during the week of August 23-27, 1998. The invited speakers will present their recent discoveries in basic or developmental research. The Division is looking for candidates who are both excellent scientists and good communicators. To nominate a chemist for this symposium, please send a letter describing the nominee's contributions to Dr. Anthony W. Czarnik IRORI Quantum Microchemistry, 11149 North Torrey Pines Road, La Jolla, CA 92037-1031, USA, and include a copy of the candidate's curriculum vitae. Deadline for receipt of nominations is February 28, 1998. Enquiries to aczarnik@irori.com From owner-repertoires@net.bio.net Thu Jan 22 22:00:00 1998 Path: biosci!biosci!not-for-mail From: S. Krishnaswamy Newsgroups: bionet.molecules.repertoires Subject: Postdoctoral Positions in Coagulation Biochemistry Date: 23 Jan 1998 02:39:15 -0800 Organization: BIOSCI International Newsgroups for Molecular Biology Lines: 49 Sender: daemon@net.bio.net Approved: A.Wallace@Queens-Belfast.AC.UK Distribution: world Message-ID: <6a9r8o$bpu@mserv1.dl.ac.uk> NNTP-Posting-Host: net.bio.net Postdoctoral Positions are available to study the proteolytic enzymes of blood coagulation. These positions will become available when the laboratory relocates to the Children's Hospital of Philadelphia in the last week of February 1998. The focus of the laboratory is to use physical biochemistry, protein chemistry, enzymology and molecular biology to study the molecular basis of specificity, function and regulation of the enzyme complexes of coagulation. Candidates should possess a Ph.D. degree with a background in protein chemistry and/or enzymology. Send a curriculum vitae and the names of three references to: S. Krishnaswamy Joseph Stokes Jr. Research Institute 310 Abramson Children's Hospital of Philadelphia 34th. Street and Civic Center Boulevard Philadelphia, PA 19104 (215) 590-4521 Fax:(215) 590-3660 If you choose to respond before 02/20/98, you may do so by writing to: S. Krishnaswamy Department of Medicine Division of Hematology/Oncology Emory University 1639 Pierce Drive, 1014 WMB Atlanta, GA 30322 (404) 727-3806 Fax: (404) 727-3404 E-mail: skris01@emory.edu ------------------------------------- Sent on 01/22/98 at 18:06:11 by skris01@emory.edu S. Krishnaswamy Division of Hematology/Oncology Department of Medicine Emory University 1014 WMB, 1639 Pierce Drive Atlanta, GA 30322 Tel: (404) 727-3806 Fax: (404) 727-3404 ------------------------------------- From owner-repertoires@net.bio.net Tue Jan 27 22:00:00 1998 Path: biosci!biosci!not-for-mail From: BIOSCI Administrator Newsgroups: bionet.molecules.repertoires Subject: BIOSCI/bionet miniFAQ & Fundraiser Date: 28 Jan 1998 03:49:56 -0800 Organization: BIOSCI International Newsgroups for Molecular Biology Lines: 236 Sender: daemon@net.bio.net Approved: A.Wallace@Queens-Belfast.AC.UK Distribution: world Message-ID: <199801281000.CAA06352@net.bio.net> NNTP-Posting-Host: net.bio.net (LAST REVISION: 30-JUL-95) This BIOSCI "miniFAQ" is designed to answer the questions that come up the *most frequently*. The main BIOSCI FAQ (Frequently Asked Questions) is accessible on the World Wide Web at URL http://www.bio.net/. If you can not find an answer to your question in this or other documentation, the BIOSCI technical support staff answers e-mail queries sent to biosci-help@net.bio.net We can only answer questions about the use of the newsgroups and mailing lists. We unfortunately do not have the staff to do Internet information searches or answer scientific questions. Please post those to the appropriate BIOSCI/bionet newsgroups. Contents: -------- 0) BIOSCI NEEDS YOUR SUPPORT!! 1) Using the WWW to access the BIOSCI/bionet newsgroups. 2) What to do about "spams," i.e., junk mail, ads, etc. 3) Examples of subscribing and unsubscribing to the mailing lists. 4) The BIOSCI user address and research interest directory. 0) BIOSCI NEEDS YOUR SUPPORT!! ------------------------------ BIOSCI's government funding has been expended, and we are now operating solely from advertising revenue that we have raised from our Web site at http://www.bio.net/. We need just a few minutes of your time to help us serve you. You can do two important things which will take very little time for you individually and will immensely help us continue to help you. First, please use our WWW system at http://www.bio.net/ to access the archives. You can post or reply to messages via your Web browser as described in item #1 below. Your usage helps attract sponsors. If you contact any of our sponsors, please be sure to thank them for supporting BIOSCI. It is critical for them to get this feedback if they are to continue their sponsorship for the long term. Second, if you work for a company or organization that provides products or services of interest to the biology community, please pass this message on to your marketing or marketing communications department or other appropriate group. Please ask them to help support BIOSCI by sponsoring our Web site and explain the uses and benefits of the system to the biology community. If they are interested, they can then contact us for further information at our tech support address, biosci-help@net.bio.net. 1) Using the WWW to access the BIOSCI/bionet newsgroups. -------------------------------------------------------- As of 10 December 1995, all BIOSCI/bionet full newsgroups are accessible through the World Wide Web (WWW) at URL http://www.bio.net. One can read and reply publicly or privately to both recent postings and archived messages through one's Web browser if it is configured properly to send e-mail. Each newsgroup is equipped with its own WAIS index. The main BIOSCI home page also has access to the BIO-JOURNALS Table of Contents database WAIS index and the BIOSCI user address database described in another item further below. 2) What to do about "spams," i.e., junk mail, ads, etc. ------------------------------------------------------- BIOSCI is a set of parallel USENET newsgroups (the "bionet" groups), mailing lists, and a hypermail archive at URL http://www.bio.net/. The same postings are distributed on all media (except for a small number of mailing-list-only groups at net.bio.net). Unfortunately it is becoming a despicable practice on the Internet (by a few people out to make a fast buck) to do automated mass postings to thousands of newsgroups and mailing lists. These attempts to grab free advertising are refered to as "spams" in the usual, somewhat boneheaded, net terminology. USENET is more susceptible to this practice, and many spams originate on the USENET groups and then are passed on to the mailing lists. However, spammers also get lists of mailing addresses and hit these too, so neither medium is immune. What should you do personally if you get junk mail? --------------------------------------------------- Just delete it and move on without reading it further. Filing a protest is becoming increasingly useless because spammers are often disguising the addresses where the messages are sent from. Unless you really understand Internet mail systems, your attempt at protest by sending replies to the message will often end up being sent to the address of an innocent person that the spammer is victimizing. What can BIOSCI/bionet do to protect its newsgroups? ---------------------------------------------------- The only solution currently available is to moderate the newsgroup. If this newsgroup is already moderated, then you are in good shape. Moderation protects the USENET distribution from about 95% of the spams that are being sent to date and protects the mailing lists completely. Moderation means, however, that someone has to take the time to review each message before it goes out. We have set up software here that simply allows the moderator to forward to an address at net.bio.net messages that (s)he wishes to have distributed. This takes no more time than that needed to read the message and pass it on, say about 1 min. per message. Most newsgroups currently have a discussion leader who is responsible for their newsgroup. The discussions leaders and their e-mail addresses are listed in the BIOSCI Information Sheet which is available on the Web at http://www.bio.net/. If a newsgroup is being hit with too many junk postings, please contact the discussion leader for that group and see if there is interest in moderating the group. Please do not assume that by simply posting a complaint to the newsgroup itself, anyone on the BIOSCI staff will act on your complaint. With close to 100 newsgroups to run, the BIOSCI staff has to rely on the discussion leaders of each newsgroup to report problems directly to us at biosci-help@net.bio.net. We will moderate any of our newsgroups if the discussion leader tells us that the readership of the group wishes to do so and if a moderator is willing to do the work. For most BIOSCI/bionet groups, this entails only a few minutes of work each day. Moderating a newsgroup will resolve probably 95% of the junk postings on the USENET distribution. Unfortunately there are easy ways for determined spammers to override the moderation mechanism on USENET, but we can protect our e-mail subscribers from unwanted postings if the newsgroup is moderated. You can also access our newsgroups over the WWW at URL http://www.bio.net. While this Web interface will not stop spammers from trying to post to the groups, this will give you yet another way, besides using USENET news, to keep the junk out of your personal mail files. For those of you with local USENET news systems, the Web interface will also give you faster access to new newsgroups and recent postings. 3) Examples of subscribing and unsubscribing to the mailing lists. ------------------------------------------------------------------ PLEASE NOTE: The BIOSCI management does NOT act on subscription/unsubscription requests that are posted improperly to the newsgroups and mailing lists. People who do this only bother everyone on the lists to no avail. Please be sure to follow the proper procedures below. Gory details are in the BIOSCI Information sheets on the Web at http://www.bio.net. Below we give an example utilizing the METHODS-AND-REAGENTS list at both of our two BIOSCI sites: Users in the Americas and Pacific Rim countries who use the BIOSCI ------------------------------------------------------------------ node at computer net.bio.net: ---------------------------- A) Determine the "listname" which is the <=8 character mail address ^^^^^^^^^^^^^ for the group. These can be found in the BIOSCI Info. Sheet. For the METHODS-AND-REAGENTS group the mailing address is methods@net.bio.net. The listname is the portion of the address to the left of the @ sign, i.e., "methods". The listname is used with the "subscribe" and "unsubscribe" commands illustrated below. B) Mail all commands in the body of a mail message addressed to biosci-server@net.bio.net. Do NOT send commands to the newsgroup posting addresses! Leave the Subject: line blank, any text on it will be ignored. C) In the body of your message put one or more of the following commands with an "end" command on the last line, e.g., subscribe methods unsubscribe methods end Do NOT put your e-mail address or other text on these lines. The server only allows you to cancel your subscription if the address on your mail header matches the address on our mailing list. Please ask for help at biosci-help@net.bio.net if your address has changed, e.g., if you know you are on the list but the server tells you that you are not a member. Users in Europe, Africa, and Central Asia who use the BIOSCI node at -------------------------------------------------------------------- computer daresbury.ac.uk (also known as dl.ac.uk): ------------------------------------------------- To subscribe and unsubscribe to/from the BIOSCI lists, you need to specify the full USENET newsgroup name with "bionet-news." prepended. The USENET newsgroup names are listed in the BIOSCI Information sheet on the Web at http://www.bio.net/. For the METHODS-AND-REAGENTS list the USENET newsgroup name is bionet.molbio.methds-reagnts, thus the appropriate commands are sub bionet-news.bionet.molbio.methds-reagnts unsub bionet-news.bionet.molbio.methds-reagnts These commands are included in a message addressed to mxt@dl.ac.uk, NOT to the newsgroup mailing addresses. As usual, include the text in the body of the message as text on the Subject: line is ignored. To unsubscribe from all the lists at the UK node, use unsub bionet-news Please note that if the address in the list is different than the one in your mail message header, you will not be able to unsubscribe by this method. If you have problems, please mail biosci@daresbury.ac.uk. 4) The BIOSCI user address and research interest directory. ----------------------------------------------------------- Please take this opportunity to add your name, address, and research interest information to the BIOSCI User Address Database if you have not already done so. You can fill out the address form directly through our Web page at URL http://www.bio.net/adrform.html. The address database is reindexed nightly for WWW access (the URL is http://www.bio.net/). If you are not directly on the Internet but can reach it by e-mail, please use our waismail server to access the user directory. waismail use is described above. You can also request a user address form by e-mail from biosci-help@net.bio.net. Please check your database entry from time-to-time to see if your address information is still up-to-date. Because of our limited personnel resources, we ask that you resubmit a *complete* form to revise your entry; we only replace complete entries and do not have resources to edit old forms. From owner-repertoires@net.bio.net Tue Jan 27 22:00:00 1998 Path: biosci!biosci!not-for-mail From: Ms Helene Newsgroups: bionet.molecules.repertoires Subject: Web site for chemists Date: 28 Jan 1998 03:05:14 -0800 Organization: BIOSCI International Newsgroups for Molecular Biology Lines: 13 Sender: daemon@net.bio.net Approved: A.Wallace@Queens-Belfast.AC.UK Distribution: world Message-ID: <6an2m8$dnc@mserv1.dl.ac.uk> NNTP-Posting-Host: net.bio.net I am trying to locate a web site that has a list of chemists involved in "combinatorial chemistry" or "molecular diversity". If anyone knows the address for this site, please reply to: MsHelene@aol.com Thanks! Helene From owner-repertoires@net.bio.net Tue Jan 27 22:00:00 1998 Path: biosci!biosci!not-for-mail From: Wendy Warr Newsgroups: bionet.molecules.repertoires Subject: Re: Web site for chemists Date: 28 Jan 1998 03:49:59 -0800 Organization: BIOSCI International Newsgroups for Molecular Biology Lines: 15 Sender: daemon@net.bio.net Approved: A.Wallace@Queens-Belfast.AC.UK Distribution: world Message-ID: <6an2rf$dtt@mserv1.dl.ac.uk> NNTP-Posting-Host: net.bio.net Helene, go to http://www.5z..com/divinfo/ and choose "Scientists" Wendy Warr Dr Wendy A Warr Wendy Warr & Associates, 6 Berwick Court Holmes Chapel, Cheshire CW4 7HZ, England Tel/fax +44 (0)1477 533837 wendy@warr.com http://www.warr.com